The extent of HEs at baseline and over time was then correlated with visual acuity (VA) and retinal thickness outcomes.<h4>Results</h4>Following initiation of anti-VEGF therapy, HEs significantly increased from baseline (0.0293 ± 0.0455 mm3) to w4 (0.0328 ± 0.0492 mm3) and peaked at w12 (0.0350 ± 0.0513 mm3), but decreased by w52 (0.0165 ± 0.0275mm3) within the entire ETDRS region (P = < 0.001, respectively), as well as within the OR and IR. Here, VEGFA is linked to hypereosinophilic syndrome.